%0 Generic
%A Albanell, J.
%A Martinez, M. T. M.
%A Ramos, M.
%A O'Connor, M.
%A De la Cruz-Merino, L.
%A Santaballa Bertran, A.
%A Martinez-Janez, N.
%A Moreno, F.
%A Fernandez Perez, I.
%A Alarcon Company, J.
%A Virizuela Echaburu, J. A.
%A De la Haba Rodriguez, J.
%A Sanchez-Rovira, P.
%A Gonzalez-Cortijo, L.
%A Margeli Vila, M.
%A Sanchez Munoz, A.
%A Garau Llinas, I.
%A Casas, M.
%A Bezares Montes, S.
%A Rojo Todo, F.
%T GEICAM/2014-12 (FLIPPER) study: First analysis from a randomized phase II trial of fulvestrant (F)/palbociclib (P) versus (vs) F/placebo (PL) as first-line therapy in postmenopausal women with HR (hormone receptor)+/HER2-endocrine sensitive advanced breast cancer (ABC)
%D 2020
%@ 0923-7534
%U https://hdl.handle.net/10668/25918
%~